Transcode Therapeutics Inc
NASDAQ:RNAZ

Watchlist Manager
Transcode Therapeutics Inc Logo
Transcode Therapeutics Inc
NASDAQ:RNAZ
Watchlist
Price: 8.41 USD 0.72% Market Closed
Market Cap: 7.7m USD

RNAZ's latest stock split occurred on May 15, 2025

The company executed a 1-for-28 stock split, meaning that for every 28 shares held, investors received 1 new share.

Before the split, RNAZ traded at 0.3467 per share. Afterward, the share price was about 7.65.

The adjusted shares began trading on May 15, 2025. This was RNAZ's 4th stock split, following the previous one in Dec 4, 2024.

Last Splits:
May 15, 2025
1-for-28
Dec 4, 2024
1-for-33
Jan 16, 2024
1-for-40
May 23, 2023
1-for-20
Pre-Split Price
9.7076 0.3467
Post-Split Price
7.65
Before
After
Last Splits:
May 15, 2025
1-for-28
Dec 4, 2024
1-for-33
Jan 16, 2024
1-for-40
May 23, 2023
1-for-20

Transcode Therapeutics Inc
Stock Splits History

RNAZ Stock Splits Timeline
May 15, 2025
May 15, 2025
Split 1-for-28
/0.035714285714286
Pre-Split Price
9.7076 0.3467
Post-Split Price
7.65
Before
After
Dec 4, 2024
Dec 4, 2024
Split 1-for-33
/0.03030303030303
Pre-Split Price
252.8988 0.2737
Post-Split Price
273
Before
After
Jan 16, 2024
Jan 16, 2024
Split 1-for-40
/0.025
Pre-Split Price
4 620 0.125
Post-Split Price
3 520.44
Before
After
May 23, 2023
May 23, 2023
Split 1-for-20
/0.05
Pre-Split Price
198 918.72 0.2691
Post-Split Price
228 782.437
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
61.4 61.4 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Transcode Therapeutics Inc
Glance View

Market Cap
7m USD
Industry
Biotechnology

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2021-04-28. The company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B.

RNAZ Intrinsic Value
Not Available
Back to Top